Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial
- 1 January 2000
- journal article
- Published by Elsevier in The Lancet
- Vol. 355 (9201), 337-345
- https://doi.org/10.1016/s0140-6736(99)11179-6
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Design and Objectives of the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events (EXCITE) StudyJournal of Interventional Cardiology, 1999
- Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trialJournal of the American College of Cardiology, 1999
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable AnginaNew England Journal of Medicine, 1998
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1998
- Sustained Platelet GP IIb/IIIa Blockade With Oral Orbofiban: Interim Pharmacodynamic Results of the SOAR StudyJournal of the American College of Cardiology, 1998
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine, 1997
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988
- The Evolution of Non-Steroidal Anti-Inflammatory Drugs and their Mechanisms of ActionDrugs, 1987